ATTAIN STUDY ACLIDINIUM PDF

The ATTAIN study: Bronchodilatory effect of aclidinium bromide in chronic obstructive pulmonary disease (COPD). David Singh, Eric D. Bateman, Paul W. Jones. The ATTAIN study: Safety and tolerability of aclidinium bromide in chronic obstructive pulmonary disease. Eric D. Bateman, David Singh, Paul W. Jones, Alvar. This paper presents results from a phase III study of longer duration (Aclidinium To Treat Airway obstruction In COPD patieNts; ATTAIN), which.

Author: Samutilar Yozshuzilkree
Country: Antigua & Barbuda
Language: English (Spanish)
Genre: Health and Food
Published (Last): 24 August 2009
Pages: 229
PDF File Size: 17.40 Mb
ePub File Size: 2.56 Mb
ISBN: 130-5-15105-208-3
Downloads: 60946
Price: Free* [*Free Regsitration Required]
Uploader: Taurr

There was a problem providing the content you requested

The impact of tiotropium on mortality and exacerbations when added to inhaled corticosteroids and long-acting beta-agonist therapy in COPD. Glycopyrronium bromide Glycopyrronium bromide is a synthetic quaternary ammonium compound, which has been used for many years to reduce secretions and block cardiac vagal reflexes before surgery.

Author information Copyright and License information Disclaimer. Effect of formoterol alone and in combination with aclidinium on electrocardiograms in dogs. Subsequently, studies investigating higher doses and alternative dosing regimens were conducted, 2930 leading to two Phase III studies: Inhaler mishandling remains common in real life and is associated with reduced disease control. The author and his institution have received consulting and lecture fees from Almirall S.

  COMPUTER APPROXIMATIONS BY HART AND CHENEY PDF

J Pharmacol Exp Ther.

COPD Efficacy Study | TUDORZA® PRESSAIR® (aclidinium bromide inhalation powder)

Tiotropium versus placebo for chronic obstructive pulmonary disease. Pharmacologic and pharmacokinetic profile Preclinical studies have shown that aclidinium displays high affinity for all five muscarinic receptors, with kinetic selectivity for M 3 receptors over M 2and a shorter duration of action and a faster onset compared with tiotropium bromide. Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: Well tolerated, no anticholinergic side effects reported, no clinical effect on EKG parameters.

Aclidinium bromide for stable chronic obstructive pulmonary disease. Summary review of regulatory action.

Comparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: Cochrane Database Syst Rev. Support Center Support Center.

Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study.

Efficacy and safety of twice-daily aclidinium bromide in COPD patients: European Medicines Agency; The three LAMAs also provide patients with a choice, as each is delivered by a different device, and some patients may prefer one over another. Aclidinium has been aclidiniym evaluated in patients with COPD Table 1 29 — 39 and has also been the subject of a recent Cochrane systematic review.

Significant improvements were seen in breathlessness, health status, and COPD symptoms in the pivotal trials. A 4-year trial of tiotropium in chronic obstructive pulmonary disease.

Food and Drug Administration Tudorza Pressair: Glycopyrronium bromide is a synthetic quaternary ammonium compound, which has been used for many years to reduce secretions and block cardiac vagal reflexes before surgery. Preclinical and pharmacological studies demonstrating low systemic bioavailability and a low propensity to induce cardiac arrhythmias were translated into a favorable tolerability profile in the clinical trial program — the adverse event profile of aclidinium was similar to placebo, with a low incidence of anticholinergic and cardiac adverse events.

  FORMACJE HARMONICZNE FOREX PDF

In continuation studies, these improvements were sustained for up to 52 weeks.

Eur Respir JOctober Pooled data showed exacerbation frequency was significantly reduced with aclidinium versus placebo. Prior to peer review, Almirall S. Dosing regimens and inhaler performance may be equally important in determining relative advantages of one drug over another.

The low systemic bio-availability of aclidinium may be an advantage, but more data are needed, as this is a class of drugs with a generally low side-effect aclidinoum. The full terms of the License are available at http: Data reported as least squares mean standard error. Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profile.